# 3D Imaging Drug Design and Development – FDA Inspection, Apr 20, 2017

Source: https://www.keypedia.com/records/fda_inspections/3d-imaging-drug-design-and-development/64a48028-799f-499d-8317-f10bb4b44bfe
Source feed: FDA_Inspections

> FDA inspection 1009371 of 3D Imaging Drug Design and Development, April 20, 2017. Classification: Official Action Indicated (OAI). 10 citations under 21 CFR parts 212 and 314. Form 483 issued. 3 other FDA inspections on record for this company.

---

## Details

- Record Type: FDA Inspection
- Inspection ID: 1009371
- Company Name: 3D Imaging Drug Design and Development
- Inspection Date: 2017-04-20
- Classification: Official Action Indicated (OAI)
- Classification Code: OAI
- Project Area: Drug Quality Assurance
- Product Type: Drugs
- Center: Human Drugs
- Office Name: Center for Drug Evaluation and Research
- Citation Count: 10

## Related Documents

- [FDA Inspection 1272748 - 2025-06-13](https://www.keypedia.com/records/fda_inspections/3d-imaging-drug-design-and-development/110c05b6-92ad-4ba6-a7b3-089d7293b2a5)
- [FDA Inspection 1228168 - 2024-01-31](https://www.keypedia.com/records/fda_inspections/3d-imaging-drug-design-and-development/b62a272a-50d6-4a9e-99be-3d3008f0eb1d)
- [FDA Inspection 1076821 - 2019-01-18](https://www.keypedia.com/records/fda_inspections/3d-imaging-drug-design-and-development/fa006bb2-0ae3-48d4-a205-c84f0d757d0a)

## Related Officers

- Issuing Officer
- [FDA Associated Person](https://www.keypedia.com/people/shawn-e-larson/a3515e47-60a3-48ff-b27c-f79bd03db12b)

Company: https://www.keypedia.com/companies/3d-imaging-drug-design-and-development/52a34c85-0fab-4e15-8980-ba031bb418ce

Office: https://www.keypedia.com/offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c